N/A N=64

Delayed Nausea and Vomiting in Patients With Colorectal Cancer Receiving Oxaliplatin

Colorectal Cancer · Nausea · Vomiting

Bottom Line

View on ClinicalTrials.gov: NCT00729677 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Mar 2011

Primary outcome: Primary: Percentages of Participants by Gender Who Reported Nausea During the First Week of Chemotherapy — 64; 34; 100 percentage of participants — p=.05

Study Design & Population

Study type: Observational
Phase: N/A
Interventions: —
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Beth Israel Medical Center
Primary completion: Nov 2008

Outcome Measures

Outcome	Result	p-value
PRIMARY Percentages of Participants by Gender Who Reported Nausea During the First Week of Chemotherapy	64; 34; 100	.05
PRIMARY Impact of Nausea and Vomiting on the Patient's Quality of Life as Measured by the Functional Living Index - Emesis Scale at 5-7 Days	—	—
PRIMARY Number of Participants by History of Nausea Who Reported Nausea During the First Week of Chemotherapy	14; 17; 9; 24	—

Summary

RATIONALE: Learning how often patients experience nausea and vomiting after receiving anti-vomiting medicine and chemotherapy for colorectal cancer may help doctors plan better treatment and improve patients' quality of life. PURPOSE: This clinical trial is studying delayed nausea and vomiting in patients with colorectal cancer receiving standard anti-vomiting medicine during the first course of chemotherapy.

Eligibility Criteria

DISEASE CHARACTERISTICS:

Diagnosis of colorectal cancer
Currently receiving OR scheduled to receive the first course of either of the following chemotherapy regimens:
mFOLFOX6
FOLFOX7
No clinical or imaging evidence of brain metastasis

PATIENT CHARACTERISTICS:

Able to maintain a diary and complete a standardized quality of life questionnaire in English

PRIOR CONCURRENT THERAPY:

See Disease Characteristics
More than 90 days since prior aprepitant

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00729677). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.